Axcella Health Inc (NASDAQ:AXLA) was the recipient of a significant decrease in short interest in the month of September. As of September 30th, there was short interest totalling 40,000 shares, a decrease of 7.6% from the August 30th total of 43,300 shares. Based on an average trading volume of 12,300 shares, the short-interest ratio is currently 3.3 days. Approximately 0.5% of the shares of the stock are sold short.
Shares of AXLA stock opened at $5.23 on Thursday. The company has a current ratio of 17.42, a quick ratio of 17.42 and a debt-to-equity ratio of 0.27. Axcella Health has a 1-year low of $4.79 and a 1-year high of $15.99. The business’s fifty day simple moving average is $6.25.
Axcella Health (NASDAQ:AXLA) last posted its earnings results on Monday, August 12th. The company reported ($0.95) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.64) by ($0.31). Equities analysts predict that Axcella Health will post -3.82 EPS for the current fiscal year.
In other Axcella Health news, Director David R. Epstein acquired 6,941 shares of the company’s stock in a transaction that occurred on Friday, August 2nd. The shares were purchased at an average price of $7.00 per share, with a total value of $48,587.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.
A number of institutional investors have recently bought and sold shares of the business. Harbourvest Partners LLC acquired a new stake in Axcella Health in the second quarter valued at $11,442,000. KCL Capital L.P. acquired a new stake in Axcella Health in the second quarter valued at $93,000. Morgan Stanley acquired a new stake in Axcella Health in the second quarter valued at $56,000. Vanguard Group Inc. acquired a new stake in Axcella Health in the second quarter valued at $499,000. Finally, Tower Research Capital LLC TRC acquired a new stake in Axcella Health in the second quarter valued at $122,000. 62.26% of the stock is currently owned by institutional investors.
A number of brokerages recently weighed in on AXLA. Zacks Investment Research lowered Axcella Health from a “hold” rating to a “sell” rating in a report on Monday, October 7th. ValuEngine raised Axcella Health from a “hold” rating to a “buy” rating in a report on Friday, October 4th. One equities research analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $22.00.
Axcella Health Company Profile
There is no company description available for Axcella Health Inc
Recommended Story: Stop Order
Receive News & Ratings for Axcella Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axcella Health and related companies with MarketBeat.com's FREE daily email newsletter.